Comparative Pharmacology
Head-to-head clinical analysis: MINIPRESS XL versus TERAZOSIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MINIPRESS XL versus TERAZOSIN HYDROCHLORIDE.
MINIPRESS XL vs TERAZOSIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective alpha-1 adrenergic receptor antagonist; inhibits vasoconstriction and reduces peripheral vascular resistance via blockade of postsynaptic alpha-1 receptors on vascular smooth muscle.
Selective alpha-1 adrenergic receptor antagonist; inhibits vasoconstriction and relaxes smooth muscle in blood vessels and prostate.
Initial: 1 mg orally once daily at bedtime, gradually increased to 2-20 mg/day in divided doses.
Adults: Initial: 1 mg orally once daily at bedtime. May increase gradually to 2–5 mg once daily. Maximum: 20 mg/day.
None Documented
None Documented
2–3 hours in normotensive patients; prolonged to 6–10 hours in hypertension; extended by renal impairment (up to 4–6 hours in creatinine clearance <10 mL/min)
Terminal elimination half-life is 9–12 hours in patients with normal renal function; may be prolonged in renal impairment.
Renal (primarily as metabolites, ~90% in urine, <10% unchanged), biliary/fecal (~10%)
Approximately 40% of the dose is excreted in urine (20% as unchanged drug) and 60% in feces via biliary elimination.
Category C
Category A/B
Alpha-1 Blocker
Alpha-1 Blocker